Explore how quantum-ready small molecule oncology drugs are transforming precision cancer therapy. Learn how AI-driven de novo design, ultra-large virtual screening, and quantum-inspired simulations enable mutation-aware, network-level, and ADMET-optimized cancer drug discovery.
Learn what MRTX1133 is, how it selectively targets the KRAS G12D mutation, and why this first-in-class, non-covalent inhibitor is reshaping the landscape of precision oncology for pancreatic, colorectal, and lung cancers.
Discover how KRAS evolved from an “undruggable” oncogene to a validated drug target. Learn how covalent KRASG12C inhibitors like sotorasib and adagrasib work, and explore emerging noncovalent strategies for targeting other KRAS mutations in lung, colorectal, and pancreatic cancer.